-
公开(公告)号:SG11201510444SA
公开(公告)日:2016-01-28
申请号:SG11201510444S
申请日:2014-07-08
Applicant: BASF SE
Inventor: HAFNER ANDREAS , VON MÜHLENEN ADRIAN , ENGER OLIVIER , GALLINET BENJAMIN , FERRINI ROLANDO , MARJANOVIC NENAD , STALDER MARTIN , BASSET GUILLAUME , LUETOLF FABIAN
Abstract: A translucent construction element comprising a layer of translucent substrate, which contains a surface structured with nanoplanes of inclined angle relative to the substrate plane, and coated with an interrupted metallic layer covering at least a part of said nanoplanes, is characterized by a high density of interruptions in the metallic layer of low thickness; the periodicity of interruptions in the metallic layer generally is from the range 50 to 1000 nm and the thickness of the metallic layer typically is from the range 1 to 50 nm. The construction element may be integrated, for example, into windows, plastic films or sheets or glazings, especially for the purpose of light management.
-
公开(公告)号:CA2950485A1
公开(公告)日:2016-01-07
申请号:CA2950485
申请日:2015-06-24
Applicant: BASF SE
Inventor: VIERTELHAUS MARTIN , CHIODO TIZIANA , SALVADOR BEATE , VOSSEN MARCUS , HAFNER ANDREAS , HINTERMANN TOBIAS , SZELAGIEWICZ MARTIN , BLATTER FRITZ
IPC: C07D417/12 , A61K31/506
Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.
-
公开(公告)号:AU2014292323A1
公开(公告)日:2016-01-07
申请号:AU2014292323
申请日:2014-07-08
Applicant: BASF SE
Inventor: HAFNER ANDREAS , VON MUHLENEN ADRIAN , ENGER OLIVIER , GALLINET BENJAMIN , FERRINI ROLANDO , MARJANOVIC NENAD , STALDER MARTIN , BASSET GUILLAUME , LUETOLF FABIAN
Abstract: A translucent construction element comprising a layer of translucent substrate, which contains a surface structured with nanoplanes of inclined angle relative to the substrate plane, and coated with an interrupted metallic layer covering at least a part of said nanoplanes, is characterized by a high density of interruptions in the metallic layer of low thickness; the periodicity of interruptions in the metallic layer generally is from the range 50 to 1000 nm and the thickness of the metallic layer typically is from the range 1 to 50 nm. The construction element may be integrated, for example, into windows, plastic films or sheets or glazings, especially for the purpose of light management.
-
34.
公开(公告)号:MX2014015433A
公开(公告)日:2015-09-16
申请号:MX2014015433
申请日:2013-06-13
Applicant: BASF SE
Inventor: SZELAGIEWICZ MARTIN , BLATTER FRITZ , CHIODO TIZIANA , HAFNER ANDREAS , HINTERMANN TOBIAS , SALVADOR BEATE , SIEBENHAAR BERND , VOSSEN MARCUS
IPC: C07D417/12 , A61K31/506 , A61P35/00
Abstract: La presente invención se refiere a un sistema cristalino de componentes múltiples (co-cristal) que comprende un compuesto de la fórmula I (INN: Dasatinib) y un segundo compuesto seleccionado de metil-4-hidroxibenzoato, o nicotinamida, o galato de etilo, o galato de metilo, o galato de propilo, o etil maltol o vainillina, o mentol, o (1R,2S,5R)-(-), así como a un procedimiento para obtener el mismo.
-
公开(公告)号:CA2917183A1
公开(公告)日:2015-01-29
申请号:CA2917183
申请日:2014-07-22
Applicant: BASF SE
Inventor: HAFNER ANDREAS , BLATTER FRITZ , SZELAGIEWICZ MARTIN , SIEBENHAAR BERND , CHIODO TIZIANA , HINTERMANN TOBIAS , SALVADOR BEATE , VOSSEN MARCUS
IPC: A61K31/506 , A61K31/191 , A61K31/428 , A61K31/455
Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
-
公开(公告)号:CA2879792A1
公开(公告)日:2014-02-13
申请号:CA2879792
申请日:2013-08-05
Applicant: BASF SE
Inventor: HAFNER ANDREAS , BLATTER FRITZ , RODEL EVA , SZELAGIEWICZ MARTIN , CHIODO TIZIANA , HINTERMANN TOBIAS , SALVADOR BEATE , VOSSEN MARCUS
IPC: C07D249/08 , A61K31/4196 , A61P7/00
Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN:Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.
-
公开(公告)号:ES2341317T3
公开(公告)日:2010-06-18
申请号:ES01945152
申请日:2001-05-17
Applicant: BASF SE
Inventor: HAFNER ANDREAS , KIRNER HANS JURG , SCHWARZENBACH FRANZ , VAN DER SCHAAF PAUL ADRIAAN , NESVADBA PETER
IPC: C07D211/94 , B01J27/122 , C07B61/00 , C07D209/44 , C07D217/26 , C07D241/08 , C07D401/12 , C07D401/14 , C07D405/12 , C08F4/00 , C08K5/3412 , C08K5/3435 , C08L101/00 , C09K15/30 , C09K21/10
Abstract: Proceso para la preparación de un éter de amina de la fórmula A **(Ver fórmula)** en donde a es 1 ó 2; cuando a es 1, E'' es E cuando a es 2, E'' es L; E es alquilo C1-C36; alquenilo C3-C18; alquinilo C2-C18; cicloalquilo C5-C18; cicloalquenilo C5-C18; un radical de hidrocarburo bicíclico o tricíclico alifático saturado o insaturado de 7 a 12 átomos de carbono; alquilo C2-C7 o alquenilo C3-C7 sustituido por halógeno, alcoxi C1-C8 o fenoxi; heterocicloalquilo C4-C12; heterocicloalquenilo C4-C12; aralquilo C7-C15 o heteroaralquilo C4-C12, cada uno de los cuales está sustituido o no sustituido por alquilo C1-C4 o fenilo; o E es un radical de fórmula (VII) o (VIII) **(Ver fórmula)** en donde Ar es arilo C8-C10 o heteroarilo C5-C9; X es fenilo, naftilo o bifenilo, que está sustituido por 1, 2, 3 ó 4 D y opcionalmente sustituido adicionalmente por NO2, halógeno, amino, hidroxi, ciano, carboxi, alcoxi C1-C4, alquiltio C1-C4, alquilamino C1-C4 o di(alquil C1-C4)amino; D es un grupo **(Ver fórmula)** un grupo C(O)-G13 o un grupo C(O)-G9-C (O)-G13; G1 y G2, independientemente entre sí, son hidrógeno, halógeno, NO2, ciano, -CONR5R6, -(R9)COOR4, -C(O)-R7, -OR8, -SR8, -NHR8, -N(R18)2, carbamoilo, di(alquil C1-C18)carbamoilo, -C(=NR5)(NHR6), alquilo C1-C18; alquenilo C3-C18; alquinilo C3-C18, fenilalquilo C7-C9, cicloalquilo C3-C12 o heterocicloalquilo C2-C12; alquilo C1-C18 o alquenilo C3-C18 o alquinilo C3-C18 o fenilalquilo C7-C9, cicloalquilo C3-C12 o heterocicloalquilo C2-C12 substituidos por OH, halógeno, NO2, amino, ciano, carboxi, COOR21, C(O)-R22, alcoxi C1-C4, alquiltio C1-C4, alquilamino C1-C4 o di(alquil C1-C4)amino o un grupo -O-C(O)-R7; alquilo C2-C18 que está interrumpido por al menos un átomo de O y/o un grupo NR5; o son arilo C6-C10; o fenilo o naftilo que están sustituidos por alquilo C1-C4, alcoxi C1-C4, alquiltio C1-C4, halógeno, ciano, hidroxi, carboxi, COOR21, C(O)-R22, alquilamino C1-C4 o di(alquil C1-C4)amino; o G1 y G2 junto con el átomo de carbono enlazante forman un radical cicloalquilo C3-C12; G5 y G6 son independientemente entre sí H o CH3; G9 es alquileno C1-C12 o un enlace directo; G13 es alquilo C1-C18; G14 es alquilo C1-C18, cicloalquilo C5-C12, un radical acilo de un ácido carbámico o carboxílico alifático o insaturado que contiene de 2 a 18 átomos de carbono, un radical acilo de un ácido carbámico o carboxílico cicloalifático que contiene de 7 a 12 átomos de carbono, o un radical acilo de un ácido aromático que contiene de 7 a 15 átomos de carbono; G55 es H, CH3 o fenilo; G66 es -CN o un grupo de fórmula -COOR4 o -CONR5R6 o -CH2-O-G14; L es alquileno de 1 a 18 átomos de carbono, cicloalquileno de 5 a 8 átomos de carbono, cicloalquenileno de 5 a 8 átomos de carbono, alquenileno de 3 a 18 átomos de carbono, alquileno de 1 a 12 átomos de carbono sustituido por fenilo o por fenilo sustituido por alquilo de 1 a 4 átomos de carbono; o es alquileno de 4 a 18 átomos de carbono interrumpido por COO y/o fenileno; T'' es alquilo C4-C18 terciario o fenilo, cada uno de los cuales está sustituido o no sustituido por halógeno, OH, COOR21 o C(O)-R22; o T'' es cicloalquilo C5-C12; cicloalquilo C5-C12 que está interrumpido por al menos un O o -NR18-; un radical alquilo policíclico que tiene 7-18 átomos de carbono, o el mismo radical que está interrumpido por al menos un O o -NR18-; o T'' es -C(G1)(G2)-T''''; o alquilo C1-C18 o cicloalquilo C5-C12 sustituido por **(Ver fórmula)** T'''' es hidrógeno, halógeno, NO2, ciano, o es un radical orgánico monovalente que contiene 1-50 átomos de carbono; o T'''' y T'' forman juntos un grupo orgánico divalente de enlazamiento que completa, junto con el átomo de nitrógeno de la amina impedida y el átomo de carbono cuaternario sustituido por G1 y G2, una estructura anular de cinco o seis miembros opcionalmente sustituida; y R4 es hidrógeno, alquilo C1-C18, fenilo, un catión de metal alcalino o un catión de tetraalquilamonio; R5 y R6 son hidrógeno, alquilo C1-C18, alquilo C2-C18 que está sustituido por hidroxi o, tomados juntos, forman un puente alquileno C2-C12 o un puente alquileno C2-C12 interrumpido por O o/y NR18; R7 es hidrógeno, alquilo C1-C18 o arilo C6-C10; R8 es hidrógeno, alquilo C1-C18 o hidroxialquilo C2-C18; R9 es alquileno C1-C12 o un enlace directo; R18 es alquilo C1-C18 o fenilo, que está sustituido o nos sustituido por halógeno, OH, COOR21 o C(O)-R22; R21 es hidrógeno, un átomo de metal alcalino o alquilo C1-C18; y R22 es alquilo C1-C18; cuyo proceso comprende la reacción de una N-oxil amina de fórmula B **(Ver fórmula)**
-
公开(公告)号:DE60141575D1
公开(公告)日:2010-04-29
申请号:DE60141575
申请日:2001-05-17
Applicant: BASF SE
Inventor: HAFNER ANDREAS , KIRNER HANS JUERG , SCHWARZENBACH FRANZ , VAN DER SCHAAF PAUL ADRIAAN , NESVADBA PETER
IPC: C07D211/94 , B01J27/122 , C07B61/00 , C07D209/44 , C07D217/26 , C07D241/08 , C07D401/12 , C07D401/14 , C07D405/12 , C08F4/00 , C08K5/3412 , C08K5/3435 , C08L101/00 , C09K15/30 , C09K21/10
Abstract: An amine ether of formula A wherein a is 1 or 2; and when a is 1, E is E'; when a is 2, E is L; E' is C 1 -C 36 alkyl; C 3 -C 18 alkenyl; C 2 -C 18 alkinyl; C 5 -C 18 cycloalkyl; C 5 -C 18 cycloalkenyl; a radical of a saturated or unsaturated aliphatic bicyclic or tricyclic hydrocarbon of 7 to 12 carbon atoms; C 2 -C 7 alkyl or C 3 -C 7 alkenyl substituted by halogen; C 7 -C 15 aralkyl or C 7 -C 15 aralkyl substituted by C 1 -C 4 alkyl or phenyl; or E' is a radical of formula (VII) as explained in claim 1; T' is tertiary C 4 -C 18 alkyl or phenyl, each of which are unsubstituted or substituted by halogen, OH, COOR 21 or C(O)-R 22 ; or T' is C 5 -C 12 cycloalkyl; C 5 -C 12 cycloalkyl which is interrupted by at least one O or -NR 18 -; a polycyclic alkyl radical having 7-18 carbon atoms, or the same radical which is interrupted by at least one O or -NR 18 -; or T' is -C(G 1 )(G 2 )-T''; or C 1 -C 18 alkyl or C 5 -C 12 cycloalkyl substituted by T'' is hydrogen, halogen, NO 2 , cyano, or is a monovalent organic radical comprising 1-50 carbon atoms; or T'' and T' together form a divalent organic linking group completing, together with the hindered amine nitrogen atom and the quaternary carbon atom substituted by G 1 and G 2 , an optionally substituted five- or six-membered ring structure; and all other residues are as defined in claim 1, are obtained in good yield from the corresponding N-oxyl hindered amine precursor by reaction with a hydrocarbon E 1 -H or H-L-H in the presence of an organic hydroperoxide and a catalytic amount of copper or a copper compound. The products of present process find utility as polymerization regulators and/or light stabilizers for organic material.
-
公开(公告)号:AT461176T
公开(公告)日:2010-04-15
申请号:AT01945152
申请日:2001-05-17
Applicant: BASF SE
Inventor: HAFNER ANDREAS , KIRNER HANS , SCHWARZENBACH FRANZ , VAN DER SCHAAF PAUL , NESVADBA PETER
IPC: C07D211/94 , B01J27/122 , C07B61/00 , C07D209/44 , C07D217/26 , C07D241/08 , C07D401/12 , C07D401/14 , C07D405/12 , C08F4/00 , C08K5/3412 , C08K5/3435 , C08L101/00 , C09K15/30 , C09K21/10
Abstract: An amine ether of formula A wherein a is 1 or 2; and when a is 1, E is E'; when a is 2, E is L; E' is C 1 -C 36 alkyl; C 3 -C 18 alkenyl; C 2 -C 18 alkinyl; C 5 -C 18 cycloalkyl; C 5 -C 18 cycloalkenyl; a radical of a saturated or unsaturated aliphatic bicyclic or tricyclic hydrocarbon of 7 to 12 carbon atoms; C 2 -C 7 alkyl or C 3 -C 7 alkenyl substituted by halogen; C 7 -C 15 aralkyl or C 7 -C 15 aralkyl substituted by C 1 -C 4 alkyl or phenyl; or E' is a radical of formula (VII) as explained in claim 1; T' is tertiary C 4 -C 18 alkyl or phenyl, each of which are unsubstituted or substituted by halogen, OH, COOR 21 or C(O)-R 22 ; or T' is C 5 -C 12 cycloalkyl; C 5 -C 12 cycloalkyl which is interrupted by at least one O or -NR 18 -; a polycyclic alkyl radical having 7-18 carbon atoms, or the same radical which is interrupted by at least one O or -NR 18 -; or T' is -C(G 1 )(G 2 )-T''; or C 1 -C 18 alkyl or C 5 -C 12 cycloalkyl substituted by T'' is hydrogen, halogen, NO 2 , cyano, or is a monovalent organic radical comprising 1-50 carbon atoms; or T'' and T' together form a divalent organic linking group completing, together with the hindered amine nitrogen atom and the quaternary carbon atom substituted by G 1 and G 2 , an optionally substituted five- or six-membered ring structure; and all other residues are as defined in claim 1, are obtained in good yield from the corresponding N-oxyl hindered amine precursor by reaction with a hydrocarbon E 1 -H or H-L-H in the presence of an organic hydroperoxide and a catalytic amount of copper or a copper compound. The products of present process find utility as polymerization regulators and/or light stabilizers for organic material.
-
公开(公告)号:AU2014295143B9
公开(公告)日:2017-03-23
申请号:AU2014295143
申请日:2014-07-22
Applicant: BASF SE
Inventor: HAFNER ANDREAS , BLATTER FRITZ , SZELAGIEWICZ MARTIN , SIEBENHAAR BERND , CHIODO TIZIANA , HINTERMANN TOBIAS , SALVADOR BEATE , VOSSEN MARCUS
IPC: C07D417/12
Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
-
-
-
-
-
-
-
-
-